Danyan Xu

List of Publications by Year
in descending order

19 papers	281 citations	1040056 9 h-index	940533 16 g-index
22 all docs	22 docs citations	22 times ranked	371 citing authors

#	Article	IF	Citations
1	A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARÎ³ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. International Journal of Cardiology, 2013, 167, 1298-1304.	1.7	59
2	Sex differences in survival after out-of-hospital cardiac arrest: a meta-analysis. Critical Care, 2020, 24, 613.	5.8	42
3	Circular RNA in cardiovascular disease: Expression, mechanisms and clinical prospects. Journal of Cellular and Molecular Medicine, 2021, 25, 1817-1824.	3.6	39
4	Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovascular Diabetology, 2020, 19, 33.	6.8	26
5	Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Atherosclerosis, 2010, 211, 237-241.	0.8	21
6	Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2010, 88, 71-75.	2.8	18
7	Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the â€œPrime Timeâ€•of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?. Cardiovascular Drugs and Therapy, 2021, 35, 467-477.	2.6	18
8	Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice. Oncotarget, 2017, 8, 94635-94649.	1.8	14
9	Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis. Medicine (United States), 2021, 100, e24579.	1.0	10
10	Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes. Molecular BioSystems, 2017, 13, 556-564.	2.9	9
11	New insights into the roles of glucocorticoid signaling dysregulation in pathological cardiac hypertrophy. Heart Failure Reviews, 2022, 27, 1431-1441.	3.9	4
12	The S100A8-serum amyloid A3-LOX-1 cascade in atherosclerotic plaque rupture. International Journal of Cardiology, 2016, 203, 832-833.	1.7	3
13	RKIP corrects impaired beta (2)-adrenergic receptor vasodilatation in hypertension by downregulation of GRK2. International Journal of Cardiology, 2016, 207, 359-360.	1.7	3
14	Advances in the mechanism and treatment of mitochondrial quality control involved in myocardial infarction. Journal of Cellular and Molecular Medicine, 2021, 25, 7110-7121.	3.6	3
15	Aerobic exercise-based rehabilitation affects the activities of progenitor endothelial cells through EETs pathway. Medical Hypotheses, 2015, 85, 1037-1038.	1.5	2
16	Stable coronary artery disease and endothelial progenitor cells. International Journal of Cardiology, 2018, 260, 18.	1.7	2
17	Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis. Drugs, 2021, 81, 2003-2016.	10.9	2
18	Is sEHi lowering LDL-C by reducing expression of PCSK9 through SREBP2 pathway?. International Journal of Cardiology, 2016, 207, 361-362.	1.7	1

#	Article	IF	Citations
19	The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2022, 36, 263-269.	2.6	1